Three genes — CALM1, CALM2 and CALM3 — are associated with heart function. A damaging variant in CALM1 causes calmodulinopathy.
Researchers from Boston Children’s Hospital said they have found a “safe and effective” pharmaceutical therapy for treating the disease, according to a Sept. 18 news release from the hospital. The antisense oligonucleotide pharmaceutical treatment targets the CALM1 gene variant at the RNA level without affecting the other CALM genes.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
